Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Lung07: Dato-DXd plus pembrolizumab with or without platinum chemotherapy in first-line non-squamous NSCLC (PD-L1 TPS <50%)
CTR20230083Phase 3Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of datopotamab deruxtecan in non-small cell lung cancer (NSCLC), sponsored by Daiichi Sankyo Co., Ltd.. Started May 2023; status: active.
02
Drugs
datopotamab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20230083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230083.